- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00288223
Telithromycin in Acute Exacerbation of Chronic Bronchitis
December 8, 2009 updated by: Sanofi
Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults
Study objectives:
- to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis.
- to assess the long-term clinical efficacy of telithromycin by telephone at D25-D35 (V3)
- to assess the safety of telithromycin
Study Overview
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey
- Sanofi-Aventis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatients,
- With a documented history of chronic bronchitis defined by one expectoration daily for at least three consecutive months over at least two consecutive years
Presenting with an evident acute exacerbation of their disease defined by the presence of at least two of Anthonisen's criteria:
- exacerbation of dyspnea,
- increase in the expectoration volume,
- increase in the expectoration purulence,
Exclusion Criteria:
- Acute bronchitis,
- Chronic obstructive pulmonary disease, those having FEV1 value <35% (FEV1: Forced Expiratory Volume in 1 second)
- Suspected pneumonia or bronchial pneumonia,
- Paroxysmal asthma or continuous dyspnea in asthma,
- Cystic fibrosis,
- Active tuberculosis,
- Lung cancer or lung metastasis,
- Severe bronchiectasia,
- Acute respiratory decompensation,
- Chronic respiratory insufficiency associated with resting hypoxemia,
- Patients requiring hospitalization for parenteral antibiotic treatment
- Patients with suspected or known bacterial infection other than study diseases, as well as associated systemic or intra-tracheal antibiotic treatment other than study treatment,
- Participating in another clinical study with any product within 30 days before the inclusion of study
- Known immunosuppression (AIDS and/or CD4+ lymphocytes < 200/mm3, neutropenia <1500/mm3, blood diseases or terminal stage cancer)
- Cardiovasculary, neurologic or other severe diseases interfering with the compliance with study protocol or confusing with results.
Conditions associated with study medications:
- Hypersensitivity against telithromycin , macrolides or any of the excipients,
- Congenital long QT syndrome or family history of congenital long QT syndrome (this possibility should be excluded with normal ECG) or known acquired QT interval prolongation,
- Treatment with CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St-John's-wort) within 2 weeks prior to the study inclusion
- Possibility of treatment with ergot alkaloid derivatives, terfenadine, astemizole, pimozide, cisapride, simvastatin, athorvastatin or lovastatin during studies
- Congenital galactosemia, lactase deficiency glucose or galactose malabsorption syndrome,
- Pregnant or lactating women,
- Women with childbearing potential (e.g. ovulating, pre-menopausal or not surgically sterilized) and do not employ any effective contraception method The patients may not participate to the study more than once. The patients who were treated with study drugs previously may not participate to the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
telithromycin
|
one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of clinical success (cure + improvement) at TOC visit (D12-19),clinical success at TOC visit in at risk sub-populations, clinical success at follow up visit (D25-35), reinfection rates,discontinuation of treatment rates, compliance
Time Frame: D12-D19 (efficacy assessment) and D25-D35 (telephone follow-up)
|
D12-D19 (efficacy assessment) and D25-D35 (telephone follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety assessment of telithromycin (Safety will be assessed on the basis of serious and non serious adverse events)
Time Frame: At V3
|
At V3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
January 1, 2007
Study Completion (Actual)
January 1, 2007
Study Registration Dates
First Submitted
February 6, 2006
First Submitted That Met QC Criteria
February 6, 2006
First Posted (Estimate)
February 7, 2006
Study Record Updates
Last Update Posted (Estimate)
December 9, 2009
Last Update Submitted That Met QC Criteria
December 8, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Bronchial Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Acute Disease
- Bronchitis
- Bronchitis, Chronic
- Anti-Infective Agents
- Anti-Bacterial Agents
- Telithromycin
Other Study ID Numbers
- HMR3647A_4022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchitis, Chronic
-
Parc de Salut MarCompletedObstructive Chronic Bronchitis With Acute ExacerbationSpain
-
Lee's Pharmaceutical LimitedUnknownAcute Exacerbations of Chronic BronchitisChina
-
Hanlim Pharm. Co., Ltd.CompletedAcute Exacerbations of Chronic Bronchitis | Acute BronchitisKorea, Republic of
-
Villa Pineta HospitalUnknownChronic Obstructive Pulmonary Disease | Chronic Bronchitis/BronchiectasisItaly
-
Neutec Ar-Ge San ve Tic A.ŞUnknownAcute Exacerbation of Chronic Bronchitis | Community-Acquired PneumoniaeTurkey
-
Felix JF HerthUnknownObstructive Chronic Bronchitis
-
Jiangxi Qingfeng Pharmaceutical Co. Ltd.UnknownAcute Exacerbation of Chronic BronchitisChina
-
PharmaKingCompletedAcute Exacerbation of Chronic BronchitisKorea, Republic of
-
Yuhan CorporationCompletedChronic Bronchitis | Acute BronchitisKorea, Republic of
-
SanofiCompletedCommunity Acquired Pneumonia (CAP) | Acute Exacerbation of Chronic Bronchitis (AECB)
Clinical Trials on Telithromycin
-
SanofiTerminated
-
SanofiCompletedChronic BronchitisFrance, Spain, Belgium, Hungary, United States, Turkey, Tunisia, Morocco
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompleted
-
SanofiTerminatedTonsillitis | PharyngitisUnited States, Argentina, Chile, Costa Rica, Panama
-
Enanta Pharmaceuticals, IncUnknownCommunity Acquired PneumoniaUnited States